New drug INCA035784 enters human testing for rare blood cancers

NCT ID NCT07008118

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 6 times

Summary

This early-stage trial tests a new drug, INCA035784, in 120 adults with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check safety and find the right dose. Participants must have a specific genetic mutation (CALR) and have tried other treatments before.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INCA035784
What this could lead to: If successful, this could point toward a new treatment option for certain blood cancers called myeloproliferative neoplasms.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. It is small and may not lead to a working treatment. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOPROLIFERATIVE NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica
NOT_YET_RECRUITING

Florence, 50134, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
NOT_YET_RECRUITING

Bergamo, 24127, Italy
Centro Ricerche Cliniche Di Verona
NOT_YET_RECRUITING

Verona, 37134, Italy
Cliniques Universitaires Saint-Luc
NOT_YET_RECRUITING

Brussels, 01200, Belgium
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Fondazione Irccs Ca Granda Ospedale Maggiore
NOT_YET_RECRUITING

Milan, 20122, Italy
Huntsman Cancer Institute At University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Icahn School of Medicine At Mount Sinai
RECRUITING

New York, New York, 10029, United States
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, 06009, Australia
Macquarie University Hospital
RECRUITING

Sydney, New South Wales, 02109, Australia
Mayo Clinic Hospital
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic-Florida
RECRUITING

Jacksonville, Florida, 32224, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 05000, Australia
South Austin Medical Center
RECRUITING

Austin, Texas, 78704, United States
Stanford University
RECRUITING

Palo Alto, California, 94304, United States
The Alfred Hospital
RECRUITING

Melbourne, Victoria, 03004, Australia
Universitaetsklinikum Dresden
NOT_YET_RECRUITING

Dresden, 01307, Germany
Universitair Ziekenhuis Gent
NOT_YET_RECRUITING

Ghent, 09000, Belgium
Universitaire Ziekenhuizen Leuven
NOT_YET_RECRUITING

Leuven, 03000, Belgium
Universitatsklinikum Halle (Saale)
NOT_YET_RECRUITING

Halle, 06120, Germany
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
NOT_YET_RECRUITING

Mainz, 55131, Germany
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of North Carolina At Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood
RECRUITING

Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.